European Journal of Cancer
Volume 46, Issue 1 , Pages 102-109 , January 2010

Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer

  • C.G. Gerestein

      Affiliations

    • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Daniel Den Hoed/Erasmus MC University Medical Center, Rotterdam, The Netherlands
    • Department of Obstetrics and Gynecology, Albert Schweitzer Hospital, Dordrecht, The Netherlands
    • Corresponding Author InformationCorresponding author: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Erasmus MC/Daniel Den Hoed University Oncology Center, Groene Hilledijk 301, 3075 AE Rotterdam, The Netherlands. Tel.: +31 10 7041263; fax: +31 10 4391986.
    • ,
  • G.M. Nieuwenhuyzen-de Boer

      Affiliations

    • Department of Obstetrics and Gynecology, Albert Schweitzer Hospital, Dordrecht, The Netherlands
    • ,
  • M.J. Eijkemans

      Affiliations

    • Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    • ,
  • G.S. Kooi

      Affiliations

    • Department of Obstetrics and Gynecology, Albert Schweitzer Hospital, Dordrecht, The Netherlands
    • ,
  • C.W. Burger

      Affiliations

    • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Daniel Den Hoed/Erasmus MC University Medical Center, Rotterdam, The Netherlands

Received 19 June 2009 ,Revised 8 October 2009 ,Accepted 15 October 2009.

References 

  1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–1259
  2. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;
  3. Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol. 1995;16(5):349–356
  4. Winter WE, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26(1):83–89
  5. Chen SS, Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol. 1985;20(2):190–195
  6. Suzuki M, Ohwara M, Sekiguchi I, Sato I. Radical cytoreductive surgery combined with platinums-carboplatin and cisplatin chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer. 1999;9(1):54–60
  7. Heintz AP, Hacker NF, Berek JS, et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol. 1986;67(6):783–788
  8. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47(2):203–209
  9. Eisenkop SM, Spirtos NM, Friedman RL, et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90(2):390–396
  10. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72(3):278–287
  11. Engelen MJ, Kos HE, Willemse PH, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106(3):589–598
  12. Bristow RE, Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol. 2001;83(1):39–48
  13. Aletti GD, Santillan A, Eisenhauer EL, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107(1):99–106
  14. Piver MS, Baker T. The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol. 1986;24(1):1–8
  15. Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 1994;53(3):326–330
  16. Michel G, De Iaco P, Castaigne D, et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol. 1997;18(1):9–15
  17. Gerestein CG, Damhuis RA, Burger CW, Kooi GS. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol. 2009;
  18. Khuri SF. The NSQIP: a new frontier in surgery. Surgery. 2005;138(5):837–843
  19. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma I. Prognostic significance of histopathologic features–problems involved in the architectural grading system. Gynecol Oncol. 1998;70(1):2–12
  20. Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol. 1987;156(1):263–264
  21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383
  22. Khuri SF, Daley J, Henderson W, et al. The Department of Veterans Affairs’ NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. Ann Surg. 1998;228(4):491–507
  23. Waljee JF, Windisch S, Finks JF, Wong SL, Birkmeyer JD. Classifying cause of death after cancer surgery. Surg Innov. 2006;13(4):274–279
  24. Daley J, Khuri SF, Henderson W, et al. Risk adjustment of the postoperative morbidity rate for the comparative assessment of the quality of surgical care: results of the National Veterans Affairs Surgical Risk Study. J Am Coll Surg. 1997;185(4):328–340
  25. Steyerberg EW, Eijkemans MJ, Harrell FE, Habbema JD. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med. 2000;19(8):1059–1079
  26. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18(6):681–694
  27. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–387
  28. Van Houwelingen JC, Le Cessie S. Predictive value of statistical models. Stat Med. 1990;9(11):1303–1325
  29. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94(3):650–654
  30. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103(3):1083–1090
  31. Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol. 1992;79(2):168–172
  32. Alphs HH, Zahurak ML, Bristow RE, Diaz-Montes TP. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol. 2006;103(3):1048–1053
  33. Diaz-Montes TP, Zahurak ML, Giuntoli RL, et al. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol. 2005;99(2):352–357
  34. Cloven NG, Manetta A, Berman ML, Kohler MF, DiSaia PJ. Management of ovarian cancer in patients older than 80 years of Age. Gynecol Oncol. 1999;73(1):137–139
  35. Vergote I, De Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71(3):431–436
  36. Vergote I, Trope C, Amant F, et al. EORTC-GCG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC/IV ovarian, fallopian tube and peritoneal cancer. In: 12th Biennal Meeting International Gynecologic Cancer Society. Bangkok, Thailand; 2008.
  37. Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 1994;53(1):33–37
  38. Huober J, Meyer A, Wagner U, Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol. 2002;128(3):153–160
  39. Janda M, Youlden DR, Baade PD, Jackson D, Obermair A. Elderly patients with stage III or IV ovarian cancer: should they receive standard care?. Int J Gynecol Cancer. 2008;18(5):896–907

PII: S0959-8049(09)00775-8

doi: 10.1016/j.ejca.2009.10.017

European Journal of Cancer
Volume 46, Issue 1 , Pages 102-109 , January 2010

Article Tools

* Image Usage & Resolution